These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 7834615

  • 1. Increased p16 levels correlate with pRb alterations in human urothelial cells.
    Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C.
    Cancer Res; 1995 Feb 01; 55(3):493-7. PubMed ID: 7834615
    [Abstract] [Full Text] [Related]

  • 2. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells.
    Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM.
    Cancer Res; 1996 Jul 01; 56(13):2886-90. PubMed ID: 8674033
    [Abstract] [Full Text] [Related]

  • 3. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA.
    Cancer Res; 1995 Oct 15; 55(20):4531-5. PubMed ID: 7553622
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
    Geradts J, Kratzke RA, Niehans GA, Lincoln CE.
    Cancer Res; 1995 Dec 15; 55(24):6006-11. PubMed ID: 8521382
    [Abstract] [Full Text] [Related]

  • 5. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
    Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA.
    Cancer Res; 1999 Jun 15; 59(12):2957-64. PubMed ID: 10383161
    [Abstract] [Full Text] [Related]

  • 6. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN.
    Cancer Res; 1996 Jan 01; 56(1):150-3. PubMed ID: 8548755
    [Abstract] [Full Text] [Related]

  • 7. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ, Aldaz CM.
    Cancer Res; 1995 Jul 01; 55(13):2892-5. PubMed ID: 7796417
    [Abstract] [Full Text] [Related]

  • 8. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A, Gaddipati JP, Moul JW, Srivastava S.
    J Urol; 1998 May 01; 159(5):1725-30. PubMed ID: 9554401
    [Abstract] [Full Text] [Related]

  • 9. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK.
    Oncogene; 1995 Mar 16; 10(6):1061-7. PubMed ID: 7700630
    [Abstract] [Full Text] [Related]

  • 10. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK.
    Cancer Res; 1995 May 15; 55(10):2150-7. PubMed ID: 7743516
    [Abstract] [Full Text] [Related]

  • 11. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
    Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddemann W, Döhner H.
    Cancer Res; 1997 Oct 15; 57(20):4608-14. PubMed ID: 9377576
    [Abstract] [Full Text] [Related]

  • 12. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
    Sarkar S, Jülicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C, Jarrard DF, Reznikoff CA.
    Cancer Res; 2000 Jul 15; 60(14):3862-71. PubMed ID: 10919661
    [Abstract] [Full Text] [Related]

  • 13. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
    Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ.
    Oncogene; 1996 Nov 07; 13(9):1867-73. PubMed ID: 8934532
    [Abstract] [Full Text] [Related]

  • 14. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
    Sartor M, Steingrimsdottir H, Elamin F, Gäken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW, Tavassoli M.
    Br J Cancer; 1999 Apr 07; 80(1-2):79-86. PubMed ID: 10389982
    [Abstract] [Full Text] [Related]

  • 15. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
    Balázs M, Carroll P, Kerschmann R, Sauter G, Waldman FM.
    Genes Chromosomes Cancer; 1997 Jun 07; 19(2):84-9. PubMed ID: 9171998
    [Abstract] [Full Text] [Related]

  • 16. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y, Becker D.
    Oncogene; 1996 Mar 07; 12(5):1069-75. PubMed ID: 8649798
    [Abstract] [Full Text] [Related]

  • 17. Association of rat p15INK4B/p16INK4 deletions with monosomy 5 in kidney epithelial cell lines but not primary renal tumors.
    Knapek DF, Serrano M, Beach D, Trono D, Walker CL.
    Cancer Res; 1995 Apr 15; 55(8):1607-12. PubMed ID: 7712460
    [Abstract] [Full Text] [Related]

  • 18. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
    Wu Q, Possati L, Montesi M, Gualandi F, Rimessi P, Morelli C, Trabanelli C, Barbanti-Brodano G.
    Int J Cancer; 1996 Mar 15; 65(6):840-6. PubMed ID: 8631601
    [Abstract] [Full Text] [Related]

  • 19. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
    Miyamoto H, Kubota Y, Fujinami K, Dobashi Y, Kondo K, Yao M, Shuin T, Hosaka M.
    Oncol Res; 1995 Mar 15; 7(7-8):327-30. PubMed ID: 8747595
    [Abstract] [Full Text] [Related]

  • 20. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
    Le Frère-Belda MA, Cappellen D, Daher A, Gil-Diez-de-Medina S, Besse F, Abbou CC, Thiery JP, Zafrani ES, Chopin DK, Radvanyi F.
    Br J Cancer; 2001 Nov 16; 85(10):1515-21. PubMed ID: 11720438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.